Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial

Jonathan Gelfond(The University of Texas at San Antonio Health Science Center), Michael A. Liss(University of San Diego), Dharam Kaushik(Mayo Clinic), Osamah Al-Bayati(The University of Texas at San Antonio Health Science Center), Aashish Kabra(The University of Texas at San Antonio Health Science Center), Kevan Iffrig(The University of Texas at San Antonio Health Science Center)
Urologic Oncology Seminars and Original Investigations
May 17, 2018
10.1016/j.urolonc.2018.04.011
Cited by 20

Related Papers

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability
|EBioMedicine|2023|275
Diffusion-Weighted Imaging in Cancer: Physical Foundations and Applications of Restriction Spectrum Imaging
|Cancer Research|2014|264
Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer
|European Urology|2018|224
Strain-Dependent Variation in 18S Ribosomal DNA Copy Numbers in <i>Aspergillus fumigatus</i>
|Journal of Clinical Microbiology|2009|197
A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects
|Experimental Gerontology|2018|168